Anaptysbio (ANAB) Retained Earnings (2016 - 2026)
Anaptysbio posted quarterly Retained Earnings of -$146000.0 for Q1 2026, down 190.68% year-on-year from $161000.0 in Q1 2025, and up 99.98% on a QoQ basis from -$772.6 million in Q4 2025.
Anaptysbio (ANAB) has 11 years of Retained Earnings data on file, last reported at -$146000.0 in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 190.68% year-over-year to -$146000.0; the trailing twelve-month figure through Mar 2026 stood at -$146000.0 (down 190.68% YoY), and the FY2025 full-year result was -$772.6 million, down 1.74% from the prior year.
- Retained Earnings for Q1 2026 stood at -$146000.0, up from -$772.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at $759000.0 in Q3 2024 and bottomed at -$822.2 million in Q3 2025.
- The 5-year median for Retained Earnings is -$3.3 million (2023), against an average of -$178.8 million.
- The widest annual swing landed in 2024, when Retained Earnings jumped 132.3%; it then slumped 108423.19% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$5.2 million in 2022, then soared by 84.81% to -$797000.0 in 2023, then sank by 95173.15% to -$759.3 million in 2024, then retreated by 1.74% to -$772.6 million in 2025, then jumped by 99.98% to -$146000.0 in 2026.
- The last three Retained Earnings figures came in at -$146000.0 (Q1 2026), -$772.6 million (Q4 2025), and -$822.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - | -146,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -146,000.00 |
| Dec 31, 2025 | -772.56 Mn |
| Sep 30, 2025 | -822.17 Mn |
| Jun 30, 2025 | -6,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | -759.33 Mn |
| Sep 30, 2024 | 759,000.00 |
| Jun 30, 2024 | -415,000.00 |
| Mar 31, 2024 | -658.03 Mn |
| Dec 31, 2023 | -797,000.00 |
| Sep 30, 2023 | -2.35 Mn |
| Jun 30, 2023 | -3.61 Mn |
| Mar 31, 2023 | -3.27 Mn |
| Dec 31, 2022 | -5.25 Mn |
| Sep 30, 2022 | -6.01 Mn |
| Jun 30, 2022 | -3.86 Mn |
| Mar 31, 2022 | -2.43 Mn |
| Dec 31, 2021 | -422,000.00 |
| Sep 30, 2021 | -289.22 Mn |
| Jun 30, 2021 | -176,000.00 |
| Mar 31, 2021 | -111,000.00 |
| Dec 31, 2020 | -263.96 Mn |
| Sep 30, 2020 | -297.60 Mn |
| Jun 30, 2020 | -273.84 Mn |
| Mar 31, 2020 | 1.15 Mn |
| Dec 31, 2019 | 338,000.00 |
| Sep 30, 2019 | 480,000.00 |
| Jun 30, 2019 | -192.73 Mn |
| Mar 31, 2019 | 204,000.00 |
| Dec 31, 2018 | -223,000.00 |
| Sep 30, 2018 | -541,000.00 |
| Jun 30, 2018 | -677,000.00 |
| Mar 31, 2018 | -801,000.00 |
| Dec 31, 2017 | -85.03 Mn |
| Sep 30, 2017 | -78.20 Mn |
| Jun 30, 2017 | -69.08 Mn |
| Mar 31, 2017 | -66.40 Mn |
| Dec 31, 2016 | -54.92 Mn |